Ampulla of vater cancers: T-stage and histological subtype but not Dpc4 expression predict prognosis

Stefania Beghelli, Simonetta Orlandini, Patrick S. Moore, Giorgio Talamini, Paola Capelli, Giuseppe Zamboni, Massimo Falconi, Aldo Scarpa

Research output: Contribution to journalArticle

Abstract

Loss of immunohistochemical expression of Dpc4 occurs in about 50% of pancreatic ductal cancers and its loss correlates with DPC4/Smad4 gene inactivation. Dpc4 expression was also lost in 6 of 16 (37%) ampulla of Vater cancers (AVCs) previously analyzed. Furthermore, chromosomal losses involving 18q, where DPC4 is located, have been observed in 34% of AVCs and are associated with decreased survival. To evaluate the possibility that expression of Dpc4 may be correlated with survival, we analyzed 89 AVCs for inactivation of DPC4 by immunohistochemical staining. Thirty-seven cases showed no expression of Dpc4 (41%). Multivariate survival analysis was performed including age, sex, tumor size, histological subtype (intestinal or pancreatobiliary), grade of differentiation, T-stage, lymph-node metastases and Dpc4 status. T-stage and histological subtype were selected as independent prognostic factors, while Dpc4 immunostaining was not significantly associated with any clinicopathological variable, including histological subtype. Although Dpc4 expression is of no clinical relevance, its involvement in AVC gives additional weight to the hypothesis that, among all pancreatic exocrine and endocrine tumors, only AVC and common ductal adenocarcinomas have similar molecular fingerprints. Moreover, comparison of the frequencies of allelic loss on chromosomal arm 18q and the loss of Dpc4 expression (34% and 41%, respectively) is highly suggestive that DPC4 is the major target of these losses.

Original languageEnglish
Pages (from-to)19-24
Number of pages6
JournalVirchows Archiv
Volume441
Issue number1
DOIs
Publication statusPublished - 2002

Fingerprint

Ampulla of Vater
Neoplasms
Loss of Heterozygosity
Dermatoglyphics
Gene Silencing
Survival Analysis
Pancreatic Neoplasms
Adenocarcinoma
Multivariate Analysis
Lymph Nodes
Staining and Labeling
Neoplasm Metastasis
Weights and Measures

Keywords

  • Ampullary cancer
  • Carcinoma
  • DPC4/Smad4
  • Pancreas

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Beghelli, S., Orlandini, S., Moore, P. S., Talamini, G., Capelli, P., Zamboni, G., ... Scarpa, A. (2002). Ampulla of vater cancers: T-stage and histological subtype but not Dpc4 expression predict prognosis. Virchows Archiv, 441(1), 19-24. https://doi.org/10.1007/s00428-002-0625-x

Ampulla of vater cancers : T-stage and histological subtype but not Dpc4 expression predict prognosis. / Beghelli, Stefania; Orlandini, Simonetta; Moore, Patrick S.; Talamini, Giorgio; Capelli, Paola; Zamboni, Giuseppe; Falconi, Massimo; Scarpa, Aldo.

In: Virchows Archiv, Vol. 441, No. 1, 2002, p. 19-24.

Research output: Contribution to journalArticle

Beghelli, S, Orlandini, S, Moore, PS, Talamini, G, Capelli, P, Zamboni, G, Falconi, M & Scarpa, A 2002, 'Ampulla of vater cancers: T-stage and histological subtype but not Dpc4 expression predict prognosis', Virchows Archiv, vol. 441, no. 1, pp. 19-24. https://doi.org/10.1007/s00428-002-0625-x
Beghelli, Stefania ; Orlandini, Simonetta ; Moore, Patrick S. ; Talamini, Giorgio ; Capelli, Paola ; Zamboni, Giuseppe ; Falconi, Massimo ; Scarpa, Aldo. / Ampulla of vater cancers : T-stage and histological subtype but not Dpc4 expression predict prognosis. In: Virchows Archiv. 2002 ; Vol. 441, No. 1. pp. 19-24.
@article{d9520eef79924cc0b86fc42f36a02603,
title = "Ampulla of vater cancers: T-stage and histological subtype but not Dpc4 expression predict prognosis",
abstract = "Loss of immunohistochemical expression of Dpc4 occurs in about 50{\%} of pancreatic ductal cancers and its loss correlates with DPC4/Smad4 gene inactivation. Dpc4 expression was also lost in 6 of 16 (37{\%}) ampulla of Vater cancers (AVCs) previously analyzed. Furthermore, chromosomal losses involving 18q, where DPC4 is located, have been observed in 34{\%} of AVCs and are associated with decreased survival. To evaluate the possibility that expression of Dpc4 may be correlated with survival, we analyzed 89 AVCs for inactivation of DPC4 by immunohistochemical staining. Thirty-seven cases showed no expression of Dpc4 (41{\%}). Multivariate survival analysis was performed including age, sex, tumor size, histological subtype (intestinal or pancreatobiliary), grade of differentiation, T-stage, lymph-node metastases and Dpc4 status. T-stage and histological subtype were selected as independent prognostic factors, while Dpc4 immunostaining was not significantly associated with any clinicopathological variable, including histological subtype. Although Dpc4 expression is of no clinical relevance, its involvement in AVC gives additional weight to the hypothesis that, among all pancreatic exocrine and endocrine tumors, only AVC and common ductal adenocarcinomas have similar molecular fingerprints. Moreover, comparison of the frequencies of allelic loss on chromosomal arm 18q and the loss of Dpc4 expression (34{\%} and 41{\%}, respectively) is highly suggestive that DPC4 is the major target of these losses.",
keywords = "Ampullary cancer, Carcinoma, DPC4/Smad4, Pancreas",
author = "Stefania Beghelli and Simonetta Orlandini and Moore, {Patrick S.} and Giorgio Talamini and Paola Capelli and Giuseppe Zamboni and Massimo Falconi and Aldo Scarpa",
year = "2002",
doi = "10.1007/s00428-002-0625-x",
language = "English",
volume = "441",
pages = "19--24",
journal = "Virchows Archiv - A Pathological Anatomy and Histopathology",
issn = "0945-6317",
publisher = "Springer Verlag",
number = "1",

}

TY - JOUR

T1 - Ampulla of vater cancers

T2 - T-stage and histological subtype but not Dpc4 expression predict prognosis

AU - Beghelli, Stefania

AU - Orlandini, Simonetta

AU - Moore, Patrick S.

AU - Talamini, Giorgio

AU - Capelli, Paola

AU - Zamboni, Giuseppe

AU - Falconi, Massimo

AU - Scarpa, Aldo

PY - 2002

Y1 - 2002

N2 - Loss of immunohistochemical expression of Dpc4 occurs in about 50% of pancreatic ductal cancers and its loss correlates with DPC4/Smad4 gene inactivation. Dpc4 expression was also lost in 6 of 16 (37%) ampulla of Vater cancers (AVCs) previously analyzed. Furthermore, chromosomal losses involving 18q, where DPC4 is located, have been observed in 34% of AVCs and are associated with decreased survival. To evaluate the possibility that expression of Dpc4 may be correlated with survival, we analyzed 89 AVCs for inactivation of DPC4 by immunohistochemical staining. Thirty-seven cases showed no expression of Dpc4 (41%). Multivariate survival analysis was performed including age, sex, tumor size, histological subtype (intestinal or pancreatobiliary), grade of differentiation, T-stage, lymph-node metastases and Dpc4 status. T-stage and histological subtype were selected as independent prognostic factors, while Dpc4 immunostaining was not significantly associated with any clinicopathological variable, including histological subtype. Although Dpc4 expression is of no clinical relevance, its involvement in AVC gives additional weight to the hypothesis that, among all pancreatic exocrine and endocrine tumors, only AVC and common ductal adenocarcinomas have similar molecular fingerprints. Moreover, comparison of the frequencies of allelic loss on chromosomal arm 18q and the loss of Dpc4 expression (34% and 41%, respectively) is highly suggestive that DPC4 is the major target of these losses.

AB - Loss of immunohistochemical expression of Dpc4 occurs in about 50% of pancreatic ductal cancers and its loss correlates with DPC4/Smad4 gene inactivation. Dpc4 expression was also lost in 6 of 16 (37%) ampulla of Vater cancers (AVCs) previously analyzed. Furthermore, chromosomal losses involving 18q, where DPC4 is located, have been observed in 34% of AVCs and are associated with decreased survival. To evaluate the possibility that expression of Dpc4 may be correlated with survival, we analyzed 89 AVCs for inactivation of DPC4 by immunohistochemical staining. Thirty-seven cases showed no expression of Dpc4 (41%). Multivariate survival analysis was performed including age, sex, tumor size, histological subtype (intestinal or pancreatobiliary), grade of differentiation, T-stage, lymph-node metastases and Dpc4 status. T-stage and histological subtype were selected as independent prognostic factors, while Dpc4 immunostaining was not significantly associated with any clinicopathological variable, including histological subtype. Although Dpc4 expression is of no clinical relevance, its involvement in AVC gives additional weight to the hypothesis that, among all pancreatic exocrine and endocrine tumors, only AVC and common ductal adenocarcinomas have similar molecular fingerprints. Moreover, comparison of the frequencies of allelic loss on chromosomal arm 18q and the loss of Dpc4 expression (34% and 41%, respectively) is highly suggestive that DPC4 is the major target of these losses.

KW - Ampullary cancer

KW - Carcinoma

KW - DPC4/Smad4

KW - Pancreas

UR - http://www.scopus.com/inward/record.url?scp=0036304347&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036304347&partnerID=8YFLogxK

U2 - 10.1007/s00428-002-0625-x

DO - 10.1007/s00428-002-0625-x

M3 - Article

C2 - 12111196

AN - SCOPUS:0036304347

VL - 441

SP - 19

EP - 24

JO - Virchows Archiv - A Pathological Anatomy and Histopathology

JF - Virchows Archiv - A Pathological Anatomy and Histopathology

SN - 0945-6317

IS - 1

ER -